Assetmark Inc. Increases Holdings in Boston Scientific Corporation $BSX

Assetmark Inc. increased its position in Boston Scientific Corporation (NYSE:BSX) by 36.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 145,679 shares of the medical equipment provider’s stock after acquiring an additional 39,270 shares during the period. Assetmark Inc.’s holdings in Boston Scientific were worth $9,141,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Angeles Wealth Management LLC raised its stake in shares of Boston Scientific by 11.2% during the 1st quarter. Angeles Wealth Management LLC now owns 7,149 shares of the medical equipment provider’s stock worth $449,000 after buying an additional 721 shares during the last quarter. C WorldWide Group Holding A S acquired a new stake in Boston Scientific in the 1st quarter valued at about $11,295,000. Bancreek Capital Management LP purchased a new position in Boston Scientific during the 1st quarter valued at about $2,447,000. Frazier Financial Advisors LLC increased its holdings in Boston Scientific by 56.3% during the 1st quarter. Frazier Financial Advisors LLC now owns 758 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 273 shares in the last quarter. Finally, SouthState Bank Corp raised its position in Boston Scientific by 4.0% during the first quarter. SouthState Bank Corp now owns 175,072 shares of the medical equipment provider’s stock worth $10,986,000 after acquiring an additional 6,736 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BSX. Bank of America reduced their price target on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Royal Bank Of Canada cut their price objective on Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Needham & Company LLC lowered their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Finally, Jefferies Financial Group dropped their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $79.84.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger acquired 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by company insiders.

Boston Scientific Stock Performance

Boston Scientific stock opened at $43.86 on Tuesday. The stock has a fifty day moving average price of $47.99 and a 200 day moving average price of $65.29. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The firm has a market capitalization of $65.20 billion, a P/E ratio of 18.35, a PEG ratio of 0.84 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the business earned $0.75 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.35 earnings per share for the current year.

Boston Scientific declared that its board has approved a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.